RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Bio-Thera Solutions of Guangzhou has begun a China Phase I trial to examine the pharmacokinetics and safety of its BAT2506, a proposed biosimilar to Simponi® (golimumab), a Janssen treatment for arthritis/ulcerative colitis. The comparison trial is a randomized, double-blind, two-arm, parallel group study that will enroll approximately 182 healthy volunteers. Each volunteer will receive a single subcutaneous dose of either BAT2506 or Simponi. Bio-Thera develops novel drugs and biosimilars for cancer, autoimmune and cardiovascular diseases. Its other arthritis biosimilars mimic AbbVie’s Humira and Genentech’s RoActemra. Source: China Biotoday
